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Sequence-Specific Gene Correction of Cystic Fibrosis Airway Basal Cells
Varada Anirudhan, B. Tech.
Advisory Professor: Brian Davis, PhD
Cystic fibrosis (CF) is a lethal monogenic disease resulting from mutations in the
CFTR gene which encodes a protein involved in regulating anion trans-epithelial
transport. A three-base deletion in CFTR (termed as ΔF508 mutation), wherein CFTR
protein is misfolded leading to its pre-mature degradation in the endoplasmic reticulum
(ER), is the most common cause of this debilitating disease. Since CFTR is expressed
in multiple body systems, CF affects different organs, but lung pathology is the greatest
cause of death in affected patients. We achieved site-specific gene correction with an
efficiency of ~10 % in CF airway basal cells homozygous for the ΔF508 mutation. Basal
cells are a multipotent stem cell population of the respiratory epithelium and therefore,
their gene correction could provide a long-term, permanent remedy for CF. Delivery of
engineered sequence-specific zinc finger nucleases (ZFNs) and single-stranded oligo
DNA (ssODN) carrying the correcting sequence via electroporation facilitated the
correction. The gene-corrected cells upon in vitro differentiation using air-liquid interface
showed presence of fully-glycosylated mature CFTR protein as opposed to
differentiated mutant cells which synthesized only the core-glycosylated immature form.
Most importantly, we demonstrated CFTR ion channel activity in the gene-corrected
cells by Ussing chamber electrophysiology.
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CHAPTER 1: INTRODUCTION
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1.1 Cystic Fibrosis (CF)
A lethal recessive autosomal disease, cystic fibrosis (CF) is common in populations
of northern European descent with an incidence rate of about 1 in 2000 births (2).
Mutations in the gene that encodes the cystic fibrosis transmembrane regulator (CFTR)
protein results in CF. Less than 200 mutations among the ~2000 that have been
identified in the CFTR gene have been demonstrated to result in CF (2). Based on their
impact at the cellular level, the CFTR mutations fall into six distinct classes (TABLE
1.1). The most common CFTR mutation (∆F508), comprising 66% of all mutations,
belongs to class II and causes the deletion of phenylalanine at position 508 of CFTR.
The ∆F508 CFTR protein is improperly folded leading to its retention in the endoplasmic
reticulum (ER) and eventual degradation by the proteasome in a ubiquitin-dependent
fashion which drastically reduces protein delivered to the cell surface (7). CFTR channel
opening is also defective in ∆F508 CF patients (15). The CFTR gene is located on
chromosome 7, has 27 exons and the three-base-pair ∆F508 deletion occurs in
exon 11.
1.1.1 CF Pathophysiology
CFTR functions as an anion channel primarily for chloride and bicarbonate transport.
In CF patients, the epithelial cells are characterized by decreased chloride secretion
and increased sodium absorption (4). Although CF affects multiple organs including the
lungs, pancreas, liver, intestine, bones and male reproductive tract (2), the pulmonary
manifestations are the major cause for CF morbidity and mortality (3). This is because
the regulatory role of CFTR to balance salt and fluid transport is disrupted leading to
thick and sticky mucus being produced along the airway which paves the way for micro2

organisms to invade and infect the lung (14). CF lung infection is mainly caused by
Staphylococcus aureus, Hemophilus influenza, and Pseudomonas aeruginosa (4).
Other CF symptoms include maldigestion, and fat & protein malabsorption resulting
from pancreatic insufficiency (occurring in 90% of CF patients) (5), gastroesophageal
reflux (4) and symptomatic cholelithiasis (occurring in ~5% of CF patients) (6).
1.1.2 CF Treatment
The median survival when CF was first described in 1938 (8) was less than 1 year of
age and now it is 46.2 years in the United States (9) and 41 in the UK (2) owing to early
detection and improved treatment methods. Frequent prolonged courses of antibiotic
treatment help improve pulmonary function (10). Viral infection in the respiratory tract
can be prevented with the help of vaccination against measles, chicken pox and
influenza. Standard chest physical therapy, mechanical vests and directed exhalation
techniques aid in controlling airway obstruction (4). Treatment using aerosolized 7%
hypertonic saline solution has shown clinically-relevant benefits in ameliorating CF
symptoms (93, 94).
CFTR modulators are therapeutic small molecules that have proved beneficial to a
growing number of CF patients (11, 12, 13) and include “CFTR potentiators” which
increase epithelial CFTR activity & “CFTR correctors” that improve defective protein
misfolding and trafficking. The primary target of the CFTR potentiator Kalydeco®
(ivacaftor, IVA; Vertex Pharmaceuticals, Boston, MA, USA) is a Class III CFTR mutation
known as G551D in which CFTR channel has a lower open probability than wild-type
CFTR. Orkambi® (Vertex Pharmaceuticals, Boston, MA, USA), an agent containing two
compounds including lumacaftor and IVA (also known as VX809 and VX770), increases
3

CFTR protein deposition on cell surfaces by acting as molecular chaperones during
protein folding and has shown promising results in treating ∆F508 CF. Currently, in latestage clinical trials are three-drug combination (VX-659 + tezacaftor + ivacaftor)
potentially capable of treating up to 93% of CF patients, including those with the ∆F508
mutation in at least one allele (88).The CFTR modulators, however, are expensive, and
require lifetime treatment (16).
TABLE 1.1 The six classes of CFTR mutations and their respective phenotypic
defects:
Class

Defect

Example

I

defective protein production

Gly542X

II

defective protein processing

∆F508

III

defective channel regulation

G551D

IV

defective conduction

Arg117His

V

reduction in functional CFTR protein

2789 + 5G

VI

decreased CFTR stability

4326delTC

1.2 Airway Basal Cells (BCs)
The lung originates from the foregut endoderm and has two major regions: the
airways which conduct gases and the alveoli where gas exchange occurs. Although it
includes mesenchymal, endothelial and neural compartments, the epithelial cell
lineages of the lung have been best-characterized. Most of these studies have been
conducted, however, in the murine lung and therefore it is important to note that the
human lung may have additional unique properties that are yet to be studied.
4

In the proximal lung region, the upper airways and bronchi (comprising large airway
region) contain superficial epithelium and submucosal glands. Small or distal airways
(bronchioles) contain only superficial epithelium. The lung epithelium in large airways is
pseudostratified and is composed mainly of basal (BC), secretory, and ciliated cells (37)
and rare neuroendocrine cells (51). Cytokeratin 5 (CK5) and 14 (CK14) preferentially
expressed in the basal cells help them firmly attach to the basement membrane via
hemidesmosomes (38). This property contributes to the structural role of basal cells
wherein they help tether the columnar epithelial cells to the airway wall (47). They also
characteristically express the transcription factor Tp63 (p63) (45) and nerve growth
factor receptor (NGFR) (39). Boers et al. (1998) (37) showed that the distribution of
airway basal cells varies along the length of the airways with ~31% basal cells in the
largest conducting airways (diameter ≥ 4 mm) and 6% in the smallest airways (diameter
< 0.5 mm). Based on several studies (39, 40, 41, 42), there is now evidence that the
airway BCs are a multipotent stem cell population. Firstly, Randell et al. (2000) (43)
suggested the existence of stem-cell niches in the pseudostratified epithelium of mouse
trachea based on BrdU (bromodeoxyuridine/5-bromo-2’deoxyuridine) label retention
over long term after epithelial cell damage by SO2 inhalation. Hong and colleagues
(2003) (44) demonstrated that CK14-expressing basal cells proliferate and re-establish
the normal epithelium in vivo following naphthalene-induced secretory cell depletion.
Hajj et al. (2007), using an in vivo humanized nude mouse xenograft model and an in
vitro air‐liquid interface culture model, demonstrated the ability of human airway basal
cells to restore a well-differentiated and functional airway epithelium. Similar studies
were conducted by Peault B. et al (2005) (48) as well. Later in 2009, Rock et al. (39),
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through lineage-tracing studies in mouse trachea, demonstrated the ability of basal cells
in steady state to self-renew and differentiate to secretory and ciliated cells. With the
help of a novel 3-dimensional sphere forming assay, they were able to demonstrate that
BCs of both mouse trachea and human airways are a multipotent stem cell population.
Airway basal cells can be expanded in vitro using a technique involving co-culture
with irradiated 3T3-J2 feeder cells along with a Rho-associated protein kinase (ROCK)
inhibitor Y-27362 (49, 50). These cells were demonstrated to maintain their tissuespecific stem cell features in that they proliferated and differentiated to secretory and
ciliated cells. Mou et al. assessed the roles of transforming growth factor-β (TGF-β) and
bone morphogenetic protein (BMP) signaling in epithelia and demonstrated that
inhibition of these signaling pathways along with a ROCK inhibitor (termed ‘dual SMAD
inhibition’ media) aided in the long-term expansion of airway basal cells (1).
1.3 CFTR Expression in the Airway Epithelia
Although CFTR plays a vital role in maintaining normal physiology of lung epithelial
cells, it is expressed at very low levels (1-2 CFTR mRNA transcript copies per cell) (52).
This, along with the low specificity of CFTR antibodies are probably the reasons why
studies to elucidate cellular localization of CFTR have shown contradictions. Engelhardt
et al. (1992) (54), using in situ hybridization and immunofluorescence studies
demonstrated that in the human bronchus the predominant site of CFTR expression
was the submucosal glands and rare (1-3% of total cell number) “flask-like” cells
present in the submucosal gland ducts. In another study (1994) (53), similar
observations were reported; in addition, they showed that CFTR expression was
undetectable in the ciliated cells although they are believed to be involved in trans6

epithelial ion transport. Kreda and colleagues (55) detected CFTR mRNA throughout
the lung superficial epithelium and found that the expression level decreased distally.
Using immunostaining and high-resolution laser confocal microscopy techniques they
showed that CFTR was localized to the apical region of the ciliated cells. They also
observed rare cells that were intensely stained by CFTR antibodies.
Most recently, two groups (51, 56) identified a new rare lung epithelial cell population
which highly expresses CFTR. These cells, named as pulmonary ionocytes, specifically
expressed FOXI1 transcription factor and CFTR, comprise <1% of total lung epithelial
cells and expressed 54.4% of all detected CFTR mRNA. These results were based on
single-cell RNA sequencing analysis on mouse tracheal epithelial cells and in vitrodifferentiated primary human bronchus epithelial cells (HBECs). However, there is
currently no consensus regarding the relative roles for ionocytes versus ciliated cells in
functional CFTR activity in the airways.
1.4 Programmable Nuclease-mediated Gene Therapy
The inherent response of a cell to double-stranded DNA breaks (DSBs) is to follow
either of the two endogenous DNA repair pathways: non-homologous end-joining
(NHEJ) and homology-directed repair (HDR) (22). The error-prone NHEJ mechanism
results in the creation of insertions and/or deletions of nucleotides (known as INDELs)
which can result in a gene ‘knock-out”. In the presence of a donor DNA, the cell can
follow the HDR pathway to ‘edit’ or ‘correct’ the genome in the desired way.
Zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs),
and Clustered regularly interspaced short palindromic repeats (CRISPR/Cas9) are three
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nuclease systems that have proved their potential to enable genome editing (23). Each
of these programmable nucleases results in induction of sequence-specific doublestranded DNA breaks (DSBs). This forms the basis for nuclease-mediated gene
therapy.
1.4.1 ZFN-mediated Gene Therapy
ZFNs are targetable DNA cleavage reagents that are fusions of a DNA-binding
domain and a non-specific FokI endonuclease cleavage domain (FIGURE 1.1). The
DNA-binding domain includes zinc finger (ZF) motifs which are engineered to
specifically bind to the target sequence of interest and their DNA recognition ability is
context-dependent.
The ZFN monomers (ZFN-L and ZFN-R) are inactive by themselves and it is required
that two ZFN monomers bind to their adjacent DNA sites and the FokI nuclease
domains to dimerize for the ZFN to cause double-stranded DNA breaks (33). This
property served as an advantage to improve ZFN specificity to avoid off-target cleavage
and three research groups (34, 35, 36) re-designed the FokI domains (making them
obligate heterodimers) permitting cleavage only by ZFN-L/ZFN-R (and not ZFN-L/ZFN-L
or ZFN-R/ZFN-R) by which they were able to considerably reduce cytotoxicity resulting
from promiscuous cutting by the ZFNs.
Sequence-specific gene targeting can be achieved using ZFNs and has been shown
by several studies including that of Porteus (2005) (27) where one site each in β-globin
and the interleukin-2 receptor common gamma chain (IL-2Rγ) were targeted. Later, the
Sangamo Biosciences group designed ZFN pairs that mediated targeting of the hamster
dihydrofolate reductase (DHFR) gene (28) and the human chemokine receptor CCR5
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gene (29). These are examples of gene inactivation where the cell’s NHEJ machinery
resulted in gene knock-out.
As noted earlier, to add nucleotide sequences, or to ‘correct a gene sequence’
requires the introduction of a donor DNA carrying the correcting sequence along with
the DSB-inducing nuclease such as ZFNs. Urnov et al. (2005) (31) had achieved an
18% gene correction of an X-linked severe combined immunodeficiency (SCID)
mutation in the IL-2Rγ gene using site-specific ZFNs. Moehle et al. (2007) (30) achieved
5-15% targeted integration in the exon 5 region of the human IL-2Rγ gene using sitespecific ZFNs and donor DNA. Both of these studies reported selection-free gene
modification and used double-stranded DNA as donors. Chen et al. (2011) reported
evidence for efficient genome editing using ZFNs and single-stranded DNA oligos
(ssODN) where the efficiency of insertion was in the range 7% to 57% and showed that
these values were cell-type dependent (32).
1.4.2 Gene Therapy in Stem Cells
Stem cells possess self-renewal and multi-lineage differentiation potential which
makes them suitable for regenerative medicine. Several groups have reported
successful ex vivo viral-based gene delivery (with random integration of therapeutic
transgenes) in hematopoietic stem cells (HSCs) from patients with genetic diseases
such as Wiskott-Aldrich syndrome (17, 18), X-linked severe combined
immunodeficiency (SCID) (19) and β-thalassemia (20). Efficient gene editing to ablate
two clinically relevant genes CCR5 and B2M was achieved in HSCs using a
CRISPR/Cas9 nuclease system (21).

9

FIGURE 1.1 Action of Zinc Finger Nucleases: Shown here
is a pair of ZFN monomers that result in DSBs upon binding
of their DNA-binding domain (orange) to the respective DNA
sequences and dimerization of the FokI-endonuclease domains
(yellow). In the presence of a donor DNA, the cell’s DNA repair
pathway can follow homology-directed repair facilitating targeted
gene replacement (green), otherwise non-homologous end
joining pathway would be followed resulting in insertions (blue)
and deletions (red) (INDELs).

Nuclease-induced doublestranded DNA break
HOMOLOGY ARM

HOMOLOGY ARM

Gene Knock-In

Gene Knock-Out

10

Donor DNA

One of the first reports to demonstrate the potential of ZFNs to induce specific
homology-repair mediated gene targeting in human induced pluripotent stem cells
(hiPSCs) and human embryonic stem cells (hESCs) was by Zou and group (32) where
they corrected a mutant GFP reporter gene at an efficiency of 0.14-0.24 %. Specific
targeting of the OCT4 (pluripotency-associated) gene in hESCs using zinc finger
nucleases with an efficiency of 39-100 % was demonstrated (70). This study also
reported ZFN-mediated targeting of the ubiquitously-expressed PPP1R12C gene and
the gene encoding PITX3 transcription factor with efficiency ranges of 33-56% and
~11% in hESCs and hiPSCs, respectively.
1.5 CF Gene Therapy
Soon after the CFTR gene was cloned in 1989 (59, 60, 61), extensive research
commenced to cure CF using gene therapy techniques and several studies have
reported viral and non-viral techniques to facilitate CF gene therapy. Two groups (62,
63) demonstrated restoration of chloride ion defect using CFTR-expressing viral vectors
and were among the first studies to show proof-of concept for CF gene therapy. More
recently, CF gene therapy studies using adeno-associated viral vectors and lentiviral
vectors (64, 65, 66, 67) have focused more on solving viral tropism issues and reduce
host immune response, apart from trying to enhance CFTR expression levels.
In addition to delivering wild-type CFTR-expressing vectors, sequence-specific gene
correction has also been performed. Lee et al (68) used ZFN expression plasmids and a
donor plasmid containing 4.3 kb of WT CFTR sequence to repair the ΔF508 mutation
and obtained an overall efficiency of < 1%. They reasoned that the low repair level was
a consequence of the distance (203 bp) of the deletion mutation (CTT) from the ZFN
11

target site. Induced pluripotent stem cells (iPSCs) derived from CF patient fibroblasts
were corrected for the ΔF508 mutation using ZFNs and a selectable plasmid donor; in
vitro differentiation of the iPSCs towards lung lineages showed presence of fullyglycosylated CFTR protein and correction of the chloride ion defect (Crane et al) (69).
1.5.1 What Efficiency of CFTR Gene Editing is Required to Restore
Therapeutically Relevant Levels of CFTR Channel Function?
It is important to note that since CF is a recessive disease, if correction is achieved
in only one CFTR allele per cell that essentially recreates the carrier state.
Studies by Trapnell et al. (52) showed that very low levels of CFTR at 1-2 copies per
cell are expressed in the human nasal, tracheal and bronchus epithelium because of the
endogenous CFTR promoter being weak. This observation, in addition to the fact that
phenotypically normal CFTR heterozygotes express 50% abnormal CFTR mRNA
transcripts, leads to the prediction that low CFTR expression may be sufficient for
restoring CF lung epithelial functions to wild-type. Johnson et al. (56) reported that as
few as 6-10% corrected cells was sufficient to restore CF chloride ion transport levels to
normal. A study using the in vivo xenograft technique showed that 5% of
pseudostratified epithelial cells expressing CFTR corrected the CF chloride transport
defect (58). These two studies used highly-efficient viral vector promoters to express
CFTR and therefore it cannot be assured that comparable results would be obtained in
differentiated human airway epithelia where CFTR is under the control of its
endogenous promoter. To address this issue, in a set of cell mixing experiments where
freshly-isolated wild-type and CF (carrying homozygous ∆F508 mutation) airway
epithelial cells were mixed in varying proportions and in vitro differentiated using air
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liquid interface method; Farmen et al. (57) demonstrated that 20% wild-type cells
generated 70% trans-epithelial chloride current relative to airway epithelia containing
100% wild-type cells. This indicates that in order to correct chloride transport defect in
CF cells, a small fraction of CFTR-expressing cells is sufficient (57). However, the
clinical implications of these results are not yet known.
1.6. Objectives and Hypothesis
We hypothesize that ∆F508 gene correction in CF airway basal cells can restore
normal proximal airway epithelial cell function. To test this, we aimed to accomplish the
following aims:
1.6.1 Specific Aim I: Site-specific zinc finger nucleases-mediated gene
correction of ∆F508 mutation in CF airway basal cells carrying ∆F508/∆F508
mutation: ∆F508 mutation-specific ZFNs were delivered in the form of
messenger RNA (mRNA) via electroporation along with single-stranded DNA
oligo (ssODN) carrying the correcting sequence to facilitate gene correction of
CF airway basal cells. In order to assess the % genome modification, including %
NHEJ and % gene correction, PCR followed by TIDER (Tracking of Insertions
Deletions and Recombination Events) analysis and Next Generation Sequencing
analysis were performed.
1.6.2 Specific Aim II: Demonstration of CFTR functional restoration in gene
corrected-basal cells at the protein and ion channel function levels: Gene
corrected-airway basal cells were in vitro differentiated into airway
pseudostratified epithelium using air liquid interface system. In order to
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demonstrate restoration of CFTR ion channel function in these cells,
electrophysiology analysis was performed using the Ussing chamber system.
Western blot analysis was used to show presence of fully-glycosylated CFTR
protein in the corrected cells.

The approach described in this study to site-specifically correct CFTR ∆F508 could be
utilized for the following potential therapeutic approaches:
a) Edit the ∆F508 mutation in patient-derived airway basal cells ex vivo with an eventual
aim to transplant the treated cells (as a bulk mixture of edited and non-edited cells or as
expanded homogenous single-cell derived clone) back into the patient; since this is an
autologous method of therapy, there is minimal risk of systemic immunological reactions
in the host, (or)
b) Accomplish in vivo correction of ∆F508 mutation in airway basal cells.
It is important to note that since CF is a recessive disease, if correction is achieved in
only one CFTR allele the patient would now be a CF carrier, i. e., they would be relieved
from the CF symptoms.
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CHAPTER 2: MATERIALS AND METHODS
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2.1 Airway Basal Cells: Origin & Culturing
CF ∆F508/∆F508 and non-CF airway basal cells were provided to us by Dr. Scott
Randell (University of North Carolina, NC, USA). Basal cells were cultured on plates
pre-coated with ‘804G-conditioned medium’ and incubated at 37 ºC in humidified air
with 5% CO2. To prepare the 804G-conditioned medium, the 804G cell line (a rat
bladder epithelial cell line) kindly given to us by Dr. Hongmei Mou (Massachusetts
General Hospital, Boston, MA, USA) was cultured in RPMI-1640 (Sigma Aldrich)
supplemented with 10 % Fetal Bovine Serum (FBS) (HyClone) and 1% PenicillinStreptomycin (pen-strep) (Gibco) on 100 mm TC-treated culture dish (Corning®) until
they were confluent. Cells were then passaged and cultured on 225cm² culture flask
(Falcon®) at an initial seeding of 4 million cells per flask containing 50 ml medium. They
were cultured at 37 ºC in humidified air with 5% CO2. After the cells were confluent,
medium was replaced with 100 ml fresh medium, and every alternate day the medium
was collected and replaced with fresh medium, for up to 3 collections. Medium obtained
was filter-sterilized and stored at 4 ºC.
Basal cells were cultured in either the ‘dual SMAD inhibition medium (1) or
Pneumacult™-Ex Plus medium (STEMCELL Technologies), both containing 1% penstrep. Dual SMAD inhibition medium consisted of SAGM™ medium (Lonza)
supplemented with 10 µM RhoA kinase (ROCK) inhibitor Y27362 (Reagents Direct), 1
µM A-8301 (R&D Systems), 1 µM DMH-1 (R&D Systems) and 1 µM CHIR99021 (R&D
Systems); all four supplements were re-suspended in DMSO and stored at -20 ºC.
Medium was replaced on a daily basis. The cells cultured in Pneumacult™-Ex Plus
medium were fed fresh medium every alternate day until they reached ~50% confluence
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after which they were fed daily. To passage the basal cells, they were split in the ratio
1:10 after dissociation with 0.25% trypsin (Lonza) for 5-8 minutes followed by the
neutralization of trypsin by RPMI-1640 + 10% FBS.
To freeze the cells (basal or 804G), they were re-suspended in CryoStor® cryopreservative medium (STEMCELL Technologies) and kept frozen in liquid N2.
2.2 Characterization of Airway Basal Cells
Airway basal cells were characterized for basal cell-specific surface markers CD49f
and NGFR using fluorescence analysis. 200,000 cells were incubated on ice (protected
from light) for 30 minutes with αCF49f-PE (Biolegend) and/or αCD271-APC (Biolegend)
(TABLE 2.1) in 100 µl of FACS buffer (phosphate buffered saline with 1% FBS). Nonimmune IgG2a-PE and IgG1, κ-APC were used as isotype controls. Antibody-stained
cells were washed with FACS buffer and pelleted by a 5-minute centrifugation at 200g
and then re-suspended with FACS containing 0.075 µg/ml 4’,6-diamidino-2-phenylindole
(DAPI) (Life Technologies) for live cell separation. Two different lasers were used to
excite the phycoerythrin (PE) (568 nm) and allophycocyanin (APC) (633 nm) fluors.
Stained cells were analyzed on a FACS LSRII (BD Biosciences) using FACS DiVA
software (BD Biosciences).
2.3 ZFN mRNA Production In Vitro
Exon 11 set 1 and set 2 ZFN plasmids were designed and provided by Sangamo
Therapeutics and ZFN messenger RNAs (mRNAs) were synthesized by in vitro
transcription using mMESSAGE mMACHINE™ T7 Ultra Transcription kit (Invitrogen).
Briefly, template DNA was prepared by PCR amplification of 100 ng ZFN plasmid using
the primers N80pt and R560 (TABLE 2.2) and enzyme AccuPrime™ Pfx DNA
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Polymerase (Invitrogen). PCR conditions were as follows: an initial denaturation at 95
ºC for 3 minutes; 30 cycles of 95 ºC for 30 seconds denaturation, 63.6 ºC for 30
seconds annealing; 68 ºC for 2 min extension; a final extension at 68 ºC for 3 min. The
PCR product was purified by Agencourt AMPure XP (Beckman Coulter) following the
manufacturer’s instructions. The purified PCR product was used to generate mRNA with
mMESSAGE mMACHINE™ T7 Ultra Transcription kit (Invitrogen), followed by RNA
purification by MEGAclear™ Transcription Clean-Up kit as per the manufacturer’s
instructions. The quantity and quality of the RNA was assessed by Qubit™ RNA HS
Assay kit and Agilent Bioanalyzer, respectively.

TABLE 2.1 List of antibodies used for basal cell characterization
Antibody

Host

Catalog

Species

No.

Biolegend

rat

313612

1:1000

PE isotype mouse IgG2a

Invitrogen

mouse

MG2A04

1:1000

APC anti human CD271

Biolegend

mouse

345108

1:1000

Biolegend

mouse

400121

1:1000

PE antihuman/mouse

Company

Dilution

CD49f Clone: GoH3

(NGFR) clone ME20.4
APC mouse IgG1,𝛋
isotype Ctr MOPC-21
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TABLE 2.2 List of primers used in this study
Primer

Purpose

Primer Sequence (5' to 3')

ZFN mRNA

GCAGAGCTCTCTGGCTAACTAGAG

Name
N80pt

production
R560

ZFN mRNA

TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT

production

TTTTTTTTTTTTTTTTTTTCTGGCAACTAGAAGGCACA
G

#49

exon 11-Cel 1 Assay

GTAGTGTGAAGGGTTCATATGC

#50

exon 11-Cel 1 Assay

GGAGGCAAGTGAATCCTGAG

#85

PCR for Sanger

CTATCTGAATCATGTGCCC

Sequencing
#88

PCR for Sanger

TTCTCTGCTGGCAGATCAATGCTCA

Sequencing
CFi10a

PCR for Sanger

Fw

Sequencing

CFi11a

PCR for Sanger

Rv

Sequencing

CF5

Primer for TIDER

AGTCTATATTTGTTTTCCAGTGGC

TACGAGTGGAAAAGTTGCGGA

TGGGTAAGCTACTGTGAATG

Analysis
Miseq-

Primer for Next

Fw

Generation

GGGAGAACTGGAGCCTTCAG

Sequencing
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Miseq-Rv

Primer for Next

GCATATGAACCCTTCACACTAC

Generation
Sequencing
CF17Fw

RT-PCR

AGGGATTTGGGGAATTATTTG

CFex1314Rv

RT-PCR

GCTGTGTCTGTAAACTGATGGCT

52-GAPDH-

RT-PCR

TCTTTTGCGTCGCCAGCCGA

53-GAPDH-Rv

RT-PCR

CCTGCAAATGAGCCCCAGCC

CF1B

Allele-Specific

CCTTCTCTGTGAACCTCTATCA

Fw

PCR
CF7C

Allele-Specific

AGTAGAAACCACAAAGGATA

PCR
CF8C

Allele-Specific

TATAGTAACCACAAAGGATA

PCR
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Addition of the WPRE sequence to the ZFN plasmid was done by Dr. Ana Maria
Crane, a senior research scientist in our lab. Briefly, WPRE sequence was PCRamplified and cloned into the ZFN plasmid at XhoI and XbaI restriction enzymes site.
2.4 Transfection of Gene Editing Reagents
100 and 200-mer single-stranded oligo DNA was synthesized by Integrated DNA
Technologies.
Sequence of the 100-mer ssODN (5’ – 3’):
TGTTCTCAGTTTTCCTGGATTATGCCTGGCACCATTAAAGAAAATATCATCTTTGGTGTTTC
CTATGATGAATATAGATACAGAAGCGTCATCAAAGCATGCC.

Sequence of the 200-mer ssODN (5’ – 3’):
TCAGAGGGTAAAATTAAGCACAGTGGAAGAATTTCATTCTGTTCTCAGTTTTCCTGGATTAT
GCCTGGCACCATTAAAGAAAATATCATCTTTGGTGTTTCCTATGATGAATATAGATACAGAA
GCGTCATCAAAGCATGCCAACTAGAAGAGGTAAGAAACTATGTGAAAACTTTTTGATTATGC
ATATGAACCCTTCA.

All the gene editing reagents (ZFN mRNAs and ssODN), and when applicable,
TriLink CleanCap® EGFP (Enhanced Green Fluorescent Protein) mRNA, were
transfected in to basal cells via electroporation using the BTX™ ECM 830
electroporation generator (Harvard Apparatus). The cells were harvested for
electroporation using 0.25% trypsin (Lonza) (5-8 minutes), followed by the neutralization
of trypsin with 10% FBS (HyClone) and then cells were washed once with phosphate
buffered saline (PBS). Cells were pelleted by a 5-minute centrifugation at 200g and then
re-suspended in BTXpress™ solution (Harvard Apparatus) to a final concentration of
0.5 X 106 cells per 100 µl of solution. Appropriate volumes of the gene targeting
reagents or EGFP mRNA were added to this cell suspension and electroporation was
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done in BTX™ electroporation cuvettes (2mm gap, Harvard Apparatus) at Low Voltage
(LV) conditions of 250 V for 5 ms, 1 pulse. Immediately after electroporation, the cells
recovered by adding 550 µl of medium (dual SMAD inhibition or Pneumacult™-Ex Plus)
to the cuvette were equally distributed between 2 wells of a 6-well clear flat-bottomed
plate (Falcon®) pre-coated with 804G-conditioned medium. Three days post
electroporation, cells were harvested for DNA isolation, and/or expansion for further
studies.
2.5 Assessment of % Genome Modification
For the Cel 1 assay (FIGURE 2.1), 100 ng genomic DNA (gDNA) isolated from
transfected cells using GeneJET Genomic DNA Purification kit (Thermo Scientific) was
PCR-amplified using primers #49 and #50 and the enzyme Phusion High-Fidelity DNA
Polymerase (Thermo Scientific). PCR conditions were as follows: an initial denaturation
at 98 ºC for 30 seconds; 35 cycles 98 ºC for 10 seconds denaturation, 68 ºC for 20
seconds annealing, 72 ºC for 15 seconds extension; a final extension at 72 ºC for 10
minutes. The PCR product was purified by Agencourt AMPure XP (Beckman Coulter).
Denaturation of the amplicon at 98 ºC for 10 min was followed by re-annealing (95 ºC to
85 ºC at the rate 2 ºC per second, 85 ºC to 25 ºC at the rate 0.1 ºC per second) and
subsequent incubation with surveyor nuclease enzyme (IDT) at 42 ºC for 20 min. ZFNs
cause double-stranded DNA breaks (DSB) that are sealed by the cell’s inherent errorprone repair mechanism termed non-homologous end joining (NHEJ) which cause
nucleotide insertions and deletions (INDEL). The surveyor enzyme detects and cleaves
nucleotide mismatches that results from ∆F508-INDEL or INDEl1-INDEL2 hetero-duplex
formation after the denaturation-renaturation step. The cleaved DNA products were

22

resolved on a 10 % TBE gel (Invitrogen).
TIDER is a bioinformatics tool (https://tider.deskgen.com/) which we had used
extensively in this study for the purpose of assessing % NHEJ and % gene correction.
TIDER uses as its input Sanger sequence data constituting a mixture of sequences and
decomposes into individual sequences with calculated frequencies (89). DNA from
transfected and non-transfected control cells were PCR-amplified using primers
CFi10aFw & CFi11aRv and after purification of PCR products (Macherey-Nagel
NucleoSpin Gel and PCR Clean-Up kit), Sanger sequencing was done by Lone Star
Labs (Houston, TX, USA) using the primer CF5. PCR conditions were as follows: an
initial denaturation at 95 ºC for 2 minutes; 35 cycles 94 ºC for 30 seconds denaturation,
57 ºC for 30 seconds annealing, 72 ºC for 1 minute extension; a final extension at 72 ºC
for 5 minutes. The ‘guide sequence’ for the TIDER analysis was 5’AATATCATTGGTGTTTCCTA; control and reference chromatogram for the analyses
were sequences from CFTR ∆F508/∆F508 and non-CF DNA, respectively. DNA from
CFTR ∆F508/∆F508 and non-CF cells were PCR-amplified and sequenced together
with samples in the same reaction.
Next Generation Sequencing (NGS) was done by our collaborator, Sangamo, where
they used primers Miseq-Fw and Miseq-Rv for the sequencing purpose.
2.6 Isolation and Genotyping of Single-Cell Derived Clones
Flat-bottomed-96-well plate (Falcon) was first pre-coated with 1% collagen
(PureCol ® from Advanced BioMatrix), after which 30,000 ATCC-irradiated NIH3T3
fibroblasts per well per 30 µl of complete DMEM medium was added. Complete DMEM
medium included DMEM (Gibco), 10% FBS (HyClone), 1 % pen-strep and 1 %
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GlutaMAX (Gibco). The next day, to each well containing mouse fibroblast feeder layer,
airway basal cells were added at the cell density of 1 cell per well or 5 cells per well and
cultured thereafter in the conditionally-reprogrammed cell (CRC) medium at 37 ºC in
humidified air with 5% CO2. CRC medium was composed of complete DMEM medium,
F-12 Nutrient Mix (Gibco), hydrocortisone (Sigma) (25 ng/ml), EGF (Invitrogen) (0.125
µg/ml), insulin (Sigma) (5 µg/ml), fungizone/amphotericin B (Fisher) (250 ng/ml),
Gentamicin (Gibco) (10 µg/ml), cholera toxin (Sigma) (0.1 µM) and ROCK inhibitor Y27362 (Reagents Direct) (10 µM). The cells were monitored daily to confirm that a
basal cell colony emerged from single cell and the wells that contained multiple colonies
were omitted from further studies. After 5-8 days of initial seeding, when single-cell
clones were greater than 50 % confluent, they were harvested using the method of
differential trypsinization, which involved initial trypsinization using 0.05 % trypsin
(Gibco) for 15-30 seconds to detach and remove the fibroblasts, followed by
detachment of basal cell clones using 0.25% trypsin (Gibco) for 5-8 minutes. Each clone
was then seeded on to one well of an 804G-coated 48-well plate (Falcon) and cultured
in the dual SMAD inh medium. After they were ~70% confluent, each clone was
replicated into one well of a 48-well plate (Falcon) (1:4) and one well of a 12-well plate
(Falcon) (3:4). The cells from the 48-well plate were harvested for DNA isolation and
subsequent allele-specific PCR (AS-PCR) and Sanger sequencing analyses
For AS-PCR, 100 ng DNA (isolated using Macherey-Nagel NucleoSpin Tissue XS
kit) from each clone was PCR-amplified using the primer pairs CF1B/CF7C (wild-typespecific) and CF1B/CF8C (ΔF508 mutant-specific) and MyTaq™ polymerase enzyme
mix (Bioline). The PCR conditions were as follows: initial denaturation at 95 ºC for 2
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FIGURE 2.1 Schematic of Cel 1 Assay: Three days posttransfection with ZFN, DNA PCR amplification followed by
denaturation and subsequent renaturation results in DNA
mismatches (as a result of ∆F508-INDEL or INDEL1-INDEL2
hetero-duplex formation) that are detected and cleaved by
surveyor nuclease enzyme. Shown in red and blue are
insertions and deletions (INDELs) resulting from the DSB
induced by ZFNs followed by the error-prone NHEJ DNA
repair mechanism in cells.

Transfection
of airway
basal cells

DNA
isolation
PCR

Cell culturing
for 3 days

Denaturation
and re-annealing

DNA
mismatches
detected and
cleaved by
surveyor
enzyme

DNA products
separated on
10% TBE gel
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minutes; 35 cycles of 95 ºC for 30 seconds denaturation, 60 ºC for 30 seconds
annealing, 72 ºC for 1 minute extension; a final extension at 72 ºC for 5 minutes. The
PCR amplicon products were separated on a 1.4% agarose gel
For the purpose of Sanger sequencing, 100 ng DNA from each clone was PCRamplified using the primers #85 and #88 and GoTaq™ Hot Start polymerase enzyme
mix (Promega). The PCR conditions were as follows: initial denaturation at 95 ºC for 2
minutes; 35 cycles of 94 ºC for 30 seconds denaturation, 57 ºC for 30 seconds
annealing, 72 ºC for 1 minute extension; a final extension at 72 ºC for 5 minutes. The
amplicon products were purified using Nucleospin® Gel and PCR clean-up kit
(Macherey-Nagel) and Sanger sequencing was done by Lone Star Labs (Houston)
using primer #88.
2.7 In vitro Differentiation of Basal Cells by Air Liquid Interface (ALI) System
Airway basal cells were seeded on to the top chamber of a 6.5 mm Transwell® with
0.4 µm pore polyester membrane inserts (Corning) which were pre-coated with 804Gconditioned medium. 200,000 cells was initially seeded and were cultured in dual SMAD
inhibition or Pneumacult™-Ex Plus medium, added to the top and bottom chambers
until the cells were 100% confluent after which, medium was replaced by PneumacultALI medium (Stemcell Technologies) containing 1% pen-strep (Gibco). The next day,
medium from the top chamber was removed to establish air-liquid interface and the cells
were cultured this way for 4 weeks with daily feeding.
2.8 CFTR RT-PCR
Total RNA was isolated from ALI-cultured cells using NucleoSpin RNA Plus kit
(Macherey-Nagel) and cDNA synthesis was done using ImProm-II reverse transcriptase
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(ImProm-II Reverse Transcription System, Promega) after combining RNA with
Oligo(dT)15 primer. CFTR RT-PCR was performed with primers CF17Fw and
CFex1314Rv and AccuPrime™ Pfx DNA Polymerase enzyme. RT-PCR of GAPDH with
primers 52-GAPDH-Fw and 53-GAPDH-Rv was done as a control. PCR conditions were
as follows: an initial denaturation at 94 ºC for 2 minutes; 35 cycles 94 ºC for 15 seconds
denaturation, 55 ºC for 15 seconds annealing, 68 ºC for 45 seconds extension; a final
extension at 68 ºC for 2 minutes.
2.9 Histology and Immunofluorescence Studies
Hematoxylin & eosin (H&E) staining was done by Dr. Zhengmei Mao (Microscopy
Core Facility, UTHealth).
Immunofluorescence study was performed on cryo-section of cells cultured in airliquid interface membrane inserts. Briefly, the samples were fixed with 4 %
paraformaldehyde (PFA) (Electron Microscopy Sciences) in PBS at 4 ºC overnight after
thorough washing with PBS. The cells were then washed thrice with ice-cold PBS, 5 min
each. After cryopreservation using sequential sucrose treatment (first 15%, then 30 %
sucrose in PBS, for 60 min each), the insert, after removal from the transwell using a
clean surgical blade, was incubated in OCT embedding medium (Fisher) for 5 min and
then transferred into a cryomold (Andwin Scientific) and flash frozen in OCT with dry
ice. Sectioning was performed (5-8 µm) using Leica® CM1850 Cryostat and the cryosection was dried overnight. For immunostaining, the sectioned samples were first
hydrated with PBS (5 min), permeabilized with 0.25 % Triton X-100 (Sigma) in PBS for
15-30 min and blocked with 2 % bovine serum albumin (BSA) for 1 hour. Samples were
then incubated with primary antibodies in 2 % BSA (TABLE 2.3) overnight at 4 ºC,
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followed by three washes with PBS, 5 min each. They were then incubated with the
respective secondary antibodies in 2 % BSA (TABLE 2.4) at room temperature for two
hours. Followed by three 5 minute-washes in PBS, Prolong™ Gold Antifade Mountant
with DAPI (Invitrogen) was added to counter-stain and mount the samples and the
samples were cured for 24 hours. For H&E and immuno-staining, images were acquired
using Leica DMi8 microscope (Leica Microsystems) and Leica Application Suite
Software (Leica Microsystems).
For the purpose of relative quantification of the epithelial cell type, for each antibody
staining, images were captured from three random fields. In each of the field, the
number of each cell type (indicated by their respective immunostaining) was counted
relative to the total number of cells (indicated by nuclei staining by DAPI).
2.10 CFTR Western Blot Analysis
ALI-cultured cells were lysed using RIPA Lysis and Extraction Buffer (Pierce) after
washing the inserts thoroughly with PBS. To obtain protein extracts, the cells were flash
frozen and thawed twice, and centrifuged at 3000 g for 10 min (4 ºC) to collect the
supernatant containing protein. The protein concentration was determined using the
colorimetric BCA assay (Pierce). The protein samples were then prepared for
separation by gel electrophoresis in the following way: Sample Reducing Agent
(NuPAGE) and Sample Buffer (NuPAGE) was added to 60 µg of the protein
supernatant, and the total volume was made up to 50 µl with RIPA buffer (Pierce).
NuPAGE 7 % Tris-Acetate Protein Gels were used to resolve the proteins, 5 µl of
protein ladder (Precision Plus Protein™ Dual Color Standards, Biorad) was loaded in to
the gel. SDS Running Buffer (NuPAGE) was added to the outer chamber and running
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FIGURE 2.2 Schematic of air-liquid interface differentiation
(a) Basal cells were seeded on to membrane inserts with
0.4 µm pores and cultured in dual SMAD inhibition or PneumacultEx plus medium (orange) on the top and bottom chambers until
they were 100% confluent, after which (b) medium was replaced by
Pneumacult-ALI medium (yellow). (c) The next day, medium from
the top chamber was removed to establish air-liquid interface and
the cells were cultured this way for 4 weeks.

(a)

(b)

(c)

4 WEEKS
APICAL
BASAL

Cells
Membrane Insert
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TABLE 2.3 List of primary antibodies used in immunofluorescence or Western
blot analysis of ALI-cultured cells
Antibody

Company

Host

Clone

Dilution

Species
FOXJ1

Invitrogen

Mouse

2A5

1:200

FOXI1

Sigma

Rabbit

polyclonal

1:200

ACT

Sigma

Mouse

6-11B-1

1:1000

p63

Biocare

Mouse

4A4

1:100

CK5

CST

Rabbit

D4U8Q

1:200

MUC5AC

Thermo Scientific

Mouse

45M1

1:200

CFTR 596

Cystic Fibrosis

Mouse

A4

1:1000

Rabbit

polyclonal

1:2000

Foundation
Calnexin

Abcam
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TABLE 2.4 List of secondary antibodies used in immunofluorescence or Western
blot analysis of ALI-cultured cells
Antibody

Host

Company

Dilution

Fluorophore

Species
goat anti-mouse

goat

Invitrogen

1:500

Alexa555

goat anti-mouse

goat

Invitrogen

1:500

Alexa488

goat anti-rabbit

goat

Invitrogen

1:500

Alexa555

goat anti-rabbit

goat

Invitrogen

1:500

Alexa488

donkey anti-mouse

donkey

Invitrogen

1:500

Alexa555
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buffer + antioxidant (NuPAGE) was added to the inner chamber of the electrophoresis
apparatus. The gel was run for 60 min at 60 V, and then at 100 V for 3 hours. Resolved
proteins on the gel was transferred onto Hybond-C nitrocellulose transfer membrane
(Amersham Bioscience) and blocked with 5% non-fat dry milk (in PBS) (blocking buffer)
at room temperature for 30 minutes. The membrane was then incubated with CFTR
primary antibody mIgG2b 596 (1:1000; Cystic Fibrosis Foundation Therapeutics) in
blocking buffer overnight at 4 ºC. After that, the membrane was washed 4 times with
TBS + 0.1 % Tween 20 + blocking buffer (5 min per wash). This was followed by
incubation in secondary antibody HRP-linked anti-mouse (1 : 5000, Cell Signaling
Technologies) in blocking buffer overnight at at 4 ºC, subsequent washing 4 times with
TBS + 0.1 % Tween 20 + blocking buffer (5 min per wash) and detection by
chemiluminescense using Amersham ECL Prime.
2.11 Ussing Chamber Analysis
Ussing chamber electrophysiology analyses was done by Dr. Andras Rab (Dr. Eric
Sorscher lab, Emory University), our collaborator. In brief, membrane inserts were
mounted in Ussing chambers and chloride ion gradient was established by providing
low chloride Ringer solution on the apical side, regular Ringer solution on the
basolateral side. Compounds were added in the following order: 1) amiloride for 10
minutes (100 µM), apical and basolateral side, 2) forskolin for 5 minutes (10 µM), apical
and basolateral side, 3) CFTR inhibitor-172 (10 µM), apical side, and 4) UTP (100 µM),
apical side. The resulting changes in short-circuit current was calculated as ∆Isc.
2.12 Statistical Analysis
We used Microsoft Excel (Seattle, WA, USA) for all our statistical analysis. The
32

Student’s t test was used to determine significance between test and control groups. Pvalue < 0.05 were considered statistically significant.

33

CHAPTER 3: RESULTS
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3.1 Airway Basal Cell Characterization
Airway basal cells express characteristic cell surface markers such as CD49f and
NGFR. We confirmed the cell surface phenotype of our cultured non-CF and
∆F508/∆F508 airway basal cells by staining with CD49f and CD271 (NGFR) antibodies
and fluorescence analysis (FIGURE 3.1). The staining patterns were consistent with
pure basal cell populations.
3.2 Analysis of Zinc-Finger Nuclease (ZFN) Activity in Airway Basal Cells
Two sets of zinc finger nucleases (ZFNs) (namely ‘exon 11 set 1 ZFN’ and ‘exon 11
set 2 ZFN’) specific to the CFTR ∆F508 sequence were designed and provided to us as
plasmid DNA by Sangamo Therapeutics through a collaboration. Each ZFN monomer
(eg: ZFN-L or ZFN-R) consists of a DNA-binding domain and a FokI-endonuclease
domain, and following binding of ZFNs to targeted DNA sequences, dimerization results
in a double-stranded DNA break (DSB). Exon 11 ZFN sets 1 and 2 include a common
ZFN-left (ZFN-L) component with the DNA-binding domain specific for CFTR ∆F508, but
not wild-type exon 11 sequence. Each of the ZFN-right (ZFN-R) components of 1 and 2
recognizes the same target sequences but differ in the amino-acid composition
(FIGURE 3.2). Achieving reasonable levels of gene correction of CFTR ∆F508 mutation
via HDR pathway of the cell requires that ZFNs efficiently induce the DSB. Therefore,
we tested the efficiency of cutting by the ZFNs by assessing the % NHEJ (nonhomologous end joining), also denoted as % INDEL.
The ZFNs were delivered via electroporation to the cells in the form of messenger
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FIGURE 3.1 Basal cell characterization. Basal cells cultured in
‘dual SMAD inhibition’ medium were characterized for basal
cell-specific surface markers CD49f and NGFR using fluorescence
analysis. They were found to be double positive for the two
markers (Q2) consistent with being pure basal cell populations.
A) non-CF cells at passage 5. B) CFTR ∆F508/∆F508 cells at
passage 6.
A)

B)
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RNA (mRNA). ZFN plasmids were used as DNA templates for in vitro production of their
respective ZFN mRNA generated by in vitro transcription using the T7 promoter.
Sangamo Therapeutics published a report wherein they showed that inclusion of the
woodchuck hepatitis virus post-transcriptional response element (WPRE) in the 3’ UTR
of ZFN mRNA enhanced protein expression of the nuclease and also increased cutting
efficiency (71). The WPRE sequence increases protein expression by increasing mRNA
stability and/or increased translation. We therefore assayed the efficiency of the exon
11 set 1 and 2 ZFNs with and without WPRE. After three days of culturing the cells post
electroporation, the cells were harvested for genomic DNA (gDNA) isolation. The Cel 1
assay was performed as a qualitative test to check for ZFN activity. Briefly, PCR
amplification of the region surrounding the cut site followed by subsequent denaturation
and renaturation of the amplicon resulted in sequence mismatches (eg: INDEL-∆F508
and/or INDEL1/INDEL2) which were detected and cleaved by surveyor nuclease
enzyme. The resulting digested DNA was resolved by gel electrophoresis (FIGURE
3.3). An accurate determination of % NHEJ was obtained by high-throughput Next
Generation Sequencing (NGS) analysis (by our collaborator, Sangamo Therapeutics).
These data showed that indeed, addition of the WPRE sequence improved efficiency of
ZFN cleavage (~ 4 – 12 fold) (FIGURE 3.3). The dose responsiveness of ZFN mRNA
with WPRE sequence was assessed in two independent experiments and the data
showed an increase in % cutting with increase in ZFN amount (FIGURE 3.4).
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FIGURE 3.2 A) Each ZFN monomer includes a DNA-binding
domain (blue and orange) and a FokI-endonuclease domain
(green). After binding of the FokI domains, dimerization results
in double-stranded DNA breaks (DSB). B) Shown in blue and
orange are the sequences to which CFTR exon 11 ZFN-L and
ZFN-R bind, respectively. ZFN-L is specific to the CFTR ∆F508
mutant sequence.
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DNA binding domain

FokI endonuclease domain

FokI endonuclease domain
DNA binding domain
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CFTR ∆F508 mutant (exon 11)

DSB

ZFN-L
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ZFN-R

FIGURE 3.3 % NHEJ resulting from the action of ZFN mRNA +/WPRE sequence. A) Primers for Cel 1 assay are shown in purple
(forward primer) and green (reverse primer). Approximate DNA cut
site is indicated by a pair of scissors. The resulting DNA sizes upon
cleavage of mismatches (eg: INDEL-∆F508 and/or INDEL1/INDEL2)
by surveyor nuclease are ~ 300 and ~100 bp. In an experiment to
compare % cutting efficiency by ZFN +/- WPRE, 4 µg each ZFN
mRNA was transfected in to 0.5 million basal cells. B) Results of
Cel 1 assay. The presence of cleaved DNA indicates ZFN-induced
INDELs activity. C) NGS analysis quantified the % NHEJ resulting
from the action of ZFN +/- WPRE. DNA from non-transfected cells
(no ZFN) was used as a negative control.
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FIGURE 3.4 Dose response curve of ZFN + WPRE mRNA.
Two independent experiments were conducted to assess % NHEJ
resulting from the action of varying doses of ZFN + WPRE mRNA.
A) EXPT 1: Results from NGS analysis. % NHEJ was found to
increase with ZFN amount for both ZFN set 1 and set 2. B) EXPT 2:
Results from NGS analysis. Similar to that seen in experiment 1,
% cutting increased with ZFN dose. DNA from non-transfected cells
were used as negative controls in both experiments.
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6.2

We noticed variation in % NHEJ between experiments and reasoned that it may be due
to a difference in quality of the mRNA synthesized by in vitro transcription for each
experiment. Therefore, we purchased large-scale in vitro transcribed ZFN mRNA from
TriLink Technologies. Exon 11 ZFN set 1 +WPRE (since we did not see much
difference between the efficiency of set 1 and set 2 ZFNs) was manufactured using the
plasmid template that we provided to TriLink and this was used in our subsequent
experiments. To test the efficiency of the commercially-synthesized ZFN, we performed
a transfection experiment in which varying doses of ZFNs were tested (0.5 - 16 µg each
ZFN) and % NHEJ was assessed by NGS (FIGURE 3.5).
3.3 Gene Correction of CFTR ∆F508/∆F508 Airway Basal Cells
As noted earlier, gene correction is dependent upon the induction of a DSB
resulting from the action of ZFNs and the introduction of template DNA carrying the
correcting sequence. Gene correction of ∆F508 would be evidenced by the addition of
three bases (CTT) in exon 11 of CFTR. We tested the individual efficiencies of a 100
and a 200-mer single-stranded oligo donor DNA (ssODN) to facilitate ZFN-mediated
correction of the CFTR ∆F508 mutation. The 100-mer ssODN and the 200-mer ssODN
had 50 base homology and 100 base homology on each side of the ZFN cut site,
respectively (FIGURE 3.6a). In cells receiving 4 µg of each ZFN with either ~2 X 108 or
~4 X 108 copies of ssODN per cell, % genome modification was assessed 3 days posttransfection using NGS. With 2 X 108 per cell, % gene correction of 1.3 and 8.1 was
obtained using the 100 and 200-mer ssODN, respectively. With 4 X 108 copies per cell,
we obtained a % gene correction of 3.3 and 9.8 using the 100 and 200-mer ssODN,
respectively (FIGURE 3.6b). This experiment indicated that the 200-mer
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FIGURE 3.5 Dose response curve of commercially (Trilink)
in vitro transcribed ZFN + WPRE mRNA. We tested the
efficiency of TriLink ZFN mRNA using different amounts. Negative
controls were DNA from non-transfected cells and cells
transfected with 0.5 µg GFP mRNA. We suspect that decreased %
NHEJ for 12 µg was perhaps due to experimental error of some
kind.
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ssODN resulted in higher % gene correction. We thus proceeded with only the 200-mer
ssODN.
3.4 Assessment of CFTR Functional Restoration in Gene Corrected Cells
In a subsequent experiment where ~ 4 X 108 copies per cell of the 200-mer ssODN
(20 µg) and 4 µg of each ZFN mRNA were transfected into cells in duplicate reactions
(samples denoted as ‘corrected 1’ (C1) and ‘corrected 2’ (C2)), Gene correction
frequencies of 15.3% and 17.5% were measured at day 3 post electroporation (FIGURE
3.7). These cells were further expanded and assessed for CFTR functional restoration.
Basal cells do not express CFTR and therefore the corrected cells were
differentiated in vitro using the air liquid interface (ALI) system to give rise to
differentiated epithelium expressing CFTR. Briefly, basal cells were first cultured on 6.5
mm Transwell® with 0.4 µm pore polyester membrane insert (Corning) at an initial
density of ~6000 cells/mm2 in dual SMAD inh medium. After the cells were confluent,
medium was replaced in the top and bottom chamber with Pneumacult™-ALI medium.
The next day, medium was removed from the upper chamber and the cells were
cultured this way for 28 days with daily medium replacement.
We observed a decrease in the % genome modification (including both % gene
correction and % NHEJ) from cells harvested three days post-transfection (‘day 3’ data)
(e.g.: C1: 68.2 % NHEJ, 15.3 % correction) to those harvested after further expansion
(‘day 7’ data) (e.g.: C1: 58.6 % NHEJ, 8.8 % correction). We also noticed that the
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FIGURE 3.6 Gene correction of CFTR ∆F508/∆F508 basal
cells. A) The three-base deletion (CTT) (i. e. the CFTR ∆F508
mutation) is shown in red. We tested the individual efficiencies of
100- and 200-mer ssODNs to facilitate ZFN-mediated CFTR
gene correction. Blue indicates corrected sequence. B) Results
from NGS analysis to assess % NHEJ and % gene correction by
the ZFN mRNA and 100 or 200-mer ssODN. The 200-mer ssODN
was found to be more efficient.
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values obtained in the latter case was more similar to that obtained after 4 weeks of ALI
differentiation (e.g.: C1: 58.8 % NHEJ, 10.7 % correction) (FIGURE 3.7).
RNA was isolated from the ALI-differentiated cells and subsequent complementary
DNA (cDNA) synthesis followed by reverse-transcriptase PCR (RT-PCR) was
performed using primers specific to the CFTR cDNA. In the two gene-corrected samples
(C1, C2), as well as in the mutant controls (with ZFN or oligo), the CFTR cDNA was
observed to be present. This was as expected since the ∆F508 mutants synthesize
CFTR mRNA; it is only that protein processing (glycosylation, maturation and transport)
are impaired. The gene correction frequency for C1 was quite similar for cDNA (10.5%)
and gDNA (10.7%). Greater differences were observed for C2 (8.5% for cDNA and
11.1% for gDNA). We have not investigated the reason(s) for similarity versus
differences between % efficiencies in cDNA versus gDNA.
Ussing chamber electrophysiology studies were performed (by our collaborators,
Drs. Andras Rab and Eric J. Sorscher, Emory University) to assess CFTR functional
restoration in the in vitro-differentiated corrected cells. In the experiment with samples
C1 and C2, ∆Isc upon forskolin treatment was measured as 3.2 and 4.7 µA/cm 2,
respectively (and treatment with CFTRinh-172 gave ∆Isc values of -3.3 and -4.4 µA/cm2,
respectively). The forskolin-induced values were higher than in the mutant controls (p <
0.05) (FIGURE 3.9). In comparison, non-CF cells showed ∆Isc values of 13.1 µA/cm2
and -17.3 µA/cm2 upon forskolin and CFTR-inhibitor treatment, respectively. Together,
this data shows that even modest efficiencies of CFTR gene correction result in
observable restoration of CFTR ion channel activity.
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FIGURE 3.7 Gene correction experiment with 4 µg each ZFN
and 20 µg of the 200-mer ssODN: A) Timeline showing analyses
done post transfection. B) 0.5 million cells at passage 5 were
transfected. We obtained 15.3 and 17.5 % in two treated samples
(denoted as ‘corrected 1’ (C1) and ‘corrected 2’ (C2)) as assessed
three days-post transfection (day 3). The total % genome modification
decreased from day 3 to day 7 (i. e. to 8.8% and 11.3% respectively),
but the values obtained on day 7 were maintained through
ALI-differentiation (ALI diff.). Negative control included DNA from
non-transfected mutant cells (no ZFN no ssODN), expanded and
differentiated at the same time as the test samples.
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FIGURE 3.8. RNA analysis of ALI-cultured cells. A) CFTR
RT-PCR: Forward and reverse primers flanked exons 10 & 11,
and exons 13 & 14, respectively. Expected band size was
581 bp. B) GAPDH RT-PCR: Expected band size was 379 bp.
‘RT-PCR controls’ for both included PCR reactions without any
cDNA template. C) Results from NGS analyses of the gDNA
and cDNA 4 weeks post-ALI differentiation. gDNA from
ALI-differentiated non-transfected mutant cells (no ZFN no
ssODN) was used as a negative control here. We do not
yet have an explanation for the differences in % NHEJ in
gDNA versus cDNA for sample C1 and the differences in
% gene correction in DNA versus cDNA for sample C2
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3.5 Isolation of Single-Cell Clones from Bulk-Corrected Basal Cells
We then performed single-cell clonal isolation from the bulk population of genecorrected basal cells using the conditionally-reprogrammed culture (CRC) methodology
(72). Briefly, the CRC methodology involves co-culturing of airway basal cell on a feeder
layer of irradiated mouse fibroblasts together with ROCK inhibitor Y-27362. The
combination of the fibroblast feeder layer and ROCK inhibitor helps maintain basal cell
characteristics such as self-renewal, differentiation potential and clone forming ability
(73).
In our single-cell clonal isolation experiment, we seeded a single basal cell from the
C2 corrected cell population (refer SECTION 3.4 and FIGURE 3.7) into each well of a
96-well plate containing 30,000 irradiated fibroblasts. Each well was closely monitored
daily for the appearance of a single-cell derived colony (wells with more than one colony
were discontinued for further studies). After single-cell derived colonies were greater
than 50 % confluent, they were isolated using differential trypsinization technique to
avoid contamination by the fibroblast cells. The isolated basal cells were further
expanded in dual SMAD inh medium and studied. 60 single-cell clones were isolated,
out of which 45 reached senescence before they could be analyzed further. The
remaining 15 clones proliferated up to a time point where their DNA could be analyzed,
but they also experienced eventual growth arrest by senescence. We first screened the
15 clones by allele-specific PCR (AS-PCR) using the primer pairs CF1B/CF7C (wildtype-specific) and CF1B/CF8C (ΔF508-mutant-specific) (FIGURE 3.10). This was
followed by Sanger sequencing analyses (FIGURE 3.11). Out of the 15 clones that were
sequenced, 1 was WT/INDEL (clone #27), 5 were INDEL/INDEL, 3 were INDEL/ΔF508,
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FIGURE 3.9 Ussing chamber analysis of ALI-cultured
cells. After 4 weeks of ALI differentiation, Ussing chamber
assays were performed for samples C1 and C2 together
with controls. Negative controls included no ZFN no ssODN
and ssODN-alone transfection controls and ZFN-alone control.
Non-CF cells were used as a positive control. All controls were
at the same passage and were differentiated at the same time
as the test samples. A) Upon forskolin activation, the ∆Isc in the
treated samples C1 and C2 were calculated to be 3.2 and
4.7 µA/cm2, respectively. These values were significantly different
(p < 0.05) when compared with the negative controls.
B) CFTRinh-172 ∆Isc values were determined to be -3.3 and
-4.4 µA/cm2 for samples C1 and C2, respectively. These values
were significantly different (p < 0.05) when compared with the
negative controls. Data are presented as mean ± SD, 8 membrane
inserts for each condition were analyzed (n=8). * P < 0.05 versus
no ZFN no ssODN mutant control. NS indicates non-significant.
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5 were ΔF508/ΔF508, and 1 (clone #2) was amplified neither in the AS-PCR conditions
nor in the PCR conditions for Sanger sequencing (we predicted this may be due to the
presence of a large INDEL, but it was not tested further). Although we were successful
in obtaining only one clone exhibiting correction of the ∆F508 mutation, this result is
consistent with and verification of site-specific gene correction.
3.6 Optimization of ZFN Cutting Efficiency in Basal Cells Cultured in
Pneumacult™-Ex Plus Medium
Pneumacult™-Ex plus medium (referred here as ‘P-ex plus medium’ or ‘P-ex plus’) is
a defined medium produced by Stemcell Technologies for the expansion of primary
human airway epithelial cells. The manufacturer, in technical materials, provided
evidence that primary airway basal cells expanded in P-ex plus medium have significant
proliferative capacity and also retain CFTR function. This led our laboratory to compare
the proliferative and CFTR activity of basal cells cultured in the P-ex plus medium
versus dual SMAD inh medium. Dr. Shingo Suzuki of our laboratory showed that basal
cells in P-ex plus medium had higher proliferative capacity at earlier passages (earlier
than passage 8) compared to those cultured in dual SMAD inh medium (data not
shown). Furthermore, cells cultured in P-ex plus followed by ALI differentiation and
Ussing chamber analyses showed higher CFTR channel activity as a function of
passage number, as compared to dual SMAD inh cells (data not shown).
Conclusions from the study described above led to switching the culture medium for
basal cells from the dual SMAD inh medium (used in the experiments described thus
far) to P-ex plus medium. One of the other major reasons to do so was the possibility
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FIGURE 3.10 Clonal isolation experiment. A) Image at 10x
magnification showing a basal-cell clone (yellow arrowhead)
co-cultured with irradiated fibroblasts (seen surrounding the
clone) B) Shown in purple is the forward primer for the AS-PCR
we performed, reverse primer specific to CFTR WT sequence is
shown in blue, and the reverse primer specific to the ΔF508
sequence is shown in green. The red triangle depicts ΔF508.
C) 15 clones were screened using AS-PCR, each with a primer
pair specific to the wild-type allele and a primer pair specific to
the mutant allele. The expected amplicon sizes were 392 and
389 bp, respectively. Clone #2 was not amplified in these PCR
conditions. Wt/wt and mutant/mutant controls were used. Based
on this screening test, clones # 5, 13, 19, 27 and 60 (**) were
thought to give possible evidence for at least one wild-type allele.
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FIGURE 3.11 Clonal isolation experiment: Sanger sequencing
analysis. A) Clones #5, 13, 19, and 60, although shown to possibly
have at least one wild-type allele by the AS-PCR, upon sequencing
were found to be INDEL/mutant, INDEL/INDEL, INDEL/INDEL and
mutant/mutant, respectively. Clone #27 was confirmed to have one
allele with wild-type sequence. This was confirmation of site-specific
gene correction.
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that P-ex plus-cultured basal cells corrected at an early passage could perhaps retain
their proliferative abilities through clonal isolation (as opposed to the senescence we
observed) and subsequent expansion for further studies.
We tested the % cutting efficiency of ZFN + WPRE mRNA in P-ex plus-cultured
basal cells. Three identical and independent experiments were conducted. The % NHEJ
three days post-electroporation was assessed using TIDER analysis (FIGURE 3.12a).
TIDER is a bioinformatics tool which quantifies % NHEJ and % gene correction using
Sanger sequence trace decomposition. The total cell number, calculated three days
post-electroporation for all three experiments, provided information regarding the
cytotoxicity resulting from electroporation and/or ZFN cutting (FIGURE 3.12b). Based on
% cutting efficiency and the observation that 4 and 8 µg of each ZFN resulted in greater
cytotoxicity, we chose 2 µg each ZFN for optimization of gene correction conditions.
3.7 Optimization of Gene Correction in Basal Cells Cultured in Pneumacult™-Ex
Plus medium
We conducted three identical and independent experiments in which 10, 20 and 30
µg of the 200-mer ssODN was transfected along with 2 µg each ZFN mRNA. The %
NHEJ and % gene correction three days post-electroporation was assessed by TIDER
analysis (FIGURE 3.13a). Cell number at this time point was calculated as a measure of
cytotoxicity (FIGURE 3.13b). In these optimization experiments, the condition in which 2
µg each ZFN + 20 µg ssODN were transfected resulted in good frequency of correction
with acceptable losses in cell number post transfection. Therefore, we decided to test
this gene correction condition for CFTR functional restoration (FIGURE 3.13c).

59

Gene-corrected basal cells from experiments 1, 2 and 3 (FIGURE 3.13c) were
subjected to in vitro differentiation using the ALI system. To visualize pseudostratified
epithelium in the differentiated gene-corrected cells, hematoxylin and eosin staining
(H&E staining) was done (FIGURE 3.14). We could observe pseudostratification in the
corrected cells similar to that observed in the non-CF and ∆F508/∆F508 controls.
Immunofluorescence studies using airway epithelial cell type-specific markers were
performed on the differentiated gene-corrected cells. p63 and CK5 staining were used
to visualize basal cells, MUC5AC staining for secretory cells, ACT (acetylated-tubulin)
staining for ciliated cells, and FOXJ1 & FOXI1 staining to visualize ciliated cells and
ionocytes, respectively (FIGURE 3.15). Comparing the relative quantification of each
cell type (basal, secretory, ciliated and ionocytes) between the corrected cells and the
wild-type and mutant controls provided information regarding the effect of genetic
manipulation on the differentiation capacity of the corrected basal cells (FIGURE 3.16).
In total, the H&E staining and immunostaining studies show that the in vitro
differentiation abilities of the corrected basal cells were not observably affected by the
gene editing manipulation.
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FIGURE 3.12 ZFN dose response in basal cells cultured in
P-ex plus medium: A) % NHEJ as assessed by TIDER analysis.
0.5, 1, 2, 4 and 8 µg of each ZFN were tested for their cutting
efficiency in three independent and identical experiments. Genomic
DNA was analyzed three days post transfection. Genomic DNA from
cells transfected with 1 µg GFP mRNA was used as a negative control.
Mean values ± SD are presented B) Total cell number three days
post-transfection were counted from three independent experiments.
Mean values ± SD are presented.
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FIGURE 3.13 Gene correction of CFTR ∆F508/∆F508 basal
cells cultured in P-ex plus medium. A) % NHEJ and % gene
correction obtained by TIDER analysis is shown in the graph.
2 µg of each ZFN mRNA were transfected with 10, 20 and 30
µg of the 200-mer ssODN; genomic DNA was analyzed three
days post transfection. This experiment was done in triplicate.
DNA from cells transfected with 1 µg GFP mRNA was used as
a negative control. Data are presented as mean ± SD. B) Total
cell number was counted three days post-transfection for each
of the three independent experiments in which 2 µg of each ZFN
mRNA were transfected with 20 µg of the ssODN.
Mean values ± SD are presented. C) Expt 1, expt 2, and
expt 3 represent results from three independent experiments.
These three samples were chosen for further studies.
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expt 3

3.8 Demonstration of CFTR Protein Expression and Channel Activity in GeneCorrected Cells
In the non-CF control, the mature fully-glycosylated CFTR protein was detected
(~170 kDA) along with the core-glycosylated immature form (~140 kDa) whereas in the
∆F508/∆F508 control sample, only the core-glycosylated CFTR was detected. This was
as expected since ∆F508 homozygous cells do not produce mature CFTR. Most
importantly, we detected the presence of fully-glycosylated CFTR protein (as well as the
core-glycosylated form) in the corrected in vitro differentiated-cells (FIGURE 3.17).
By Ussing chamber analyses, we then assessed CFTR ion channel function
(FIGURE 3.18). After baseline establishment by amiloride treatment, addition of cAMPspecific CFTR activator forskolin resulted in increased short-circuit current in the three
differentiated gene-corrected samples. The ∆Isc values were 8.9, 9.9 and 6.0 µA/cm2,
respectively. Importantly, these values were greater than that obtained in the ∆F508
homozygous mutant control (p < 0.05). Furthermore, the use of VX809 + VX770 (the
components of Orkambi®), an FDA-approved combination drug shown to provide some
therapeutic benefit to homozygous ∆F508 patients, allowed the comparison of ∆Isc
values obtained in the corrected cells with an accepted therapeutic range. Although our
corrected samples yielded higher ∆Isc values than uncorrected ∆F508/∆F508, they did
not rise to the level of VX809 + VX770-treated samples. Collectively, these data are
evidence that the gene correction strategy in CF airway basal cells resulted in some
restoration of CFTR protein expression and ion channel activity, albeit not yet in a
therapeutic range.
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FIGURE 3.14 H&E staining of ALI-cultured cells: Histology
studies were done on the ALI-differentiated cells. ZFN + ssODN
expt 1, 2 and 3represent edited samples from three independent
repeat experiments. Representative images are shown at 20X
magnification.
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FIGURE 3.15 Immunofluorescence studies of ALI-cultured
cells: Representative images are shown at 40X magnification.
A) CK5 (red) and ACT (green) staining basal cells and cilia,
respectively. B) MUC5AC (red) and p63 (green) that stain
secretory cells and basal cels, respectively. C) FOXJ1 (green)
and FOXI1 (red) staining ciliated cell nuclei and ionocytes,
respectively. Nuclei were counter-stained with 4,6’-diamidino2-phenylindole (DAPI) (blue).
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FIGURE 3.16 Relative quantification of airway epithelial
cell-types. Followed by immunofluorescence staining with
markers specific to the cell types, images of 3 random fields
(n=3) at 40x magnification were acquired. For a particular
staining, in each of the 3 fields, cell number was counted relative
to the total cell number (depicted by DAPI staining). Relative
quantitation of basal cells (A), secretory cells (B), ciliated cells
(C) and ionocytes (D) were done. Data are presented as mean ± SD.
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FIGURE 3.17 Western blot analysis of restored CFTR
protein. Gene corrected cells (ZFN + ssODN expt 1,
ZFN + ssODN expt 2, ZFN + ssODN expt 3) showed the
presence of mature fully-glycosylated (~170 kDa) and
immature core-glycosylated (~140 kDa) CFTR protein in
contrast to the ∆F508/∆F508 control in which only coreglycosylated protein was present. This demonstrates
restored CFTR protein in gene-corrected cells. Non-CF cells
showing presence of mature and immature CFTR was used
as a positive control.

Band C ~170 kDA
Band B ~140 kDA

ZFN + ssODN
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FIGURE 3.18 Ussing chamber analysis of ALIcultured cells: After 4 weeks of ALI differentiation, Ussing
chamber analysis of CFTR function was performed. Negative
control included ∆F508/∆F508 cells. Non-CF cells were used
as a positive control. All controls were at the same passage
and were differentiated at the same time as the test samples.
Each of the values obtained upon the action of forskolin and
CFTR inh-172 in the three test samples were found to be
greater than that in the negative control (p < 0.05). ΔF508/ΔF508
cells treated with VX809 + VX770 post-ALI differentiation and
prior to electrophysiology studies served as a means of
comparing ∆Isc values obtained in the corrected cells with a
therapeutic range. Data are presented as mean ± SD, 4
membrane inserts for each condition were analyzed (n=4).
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CHAPTER 4: DISCUSSION & FUTURE DIRECTIONS
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In this study, we aimed to achieve ex vivo genetic correction of the most common
CFTR mutation ∆F508 in airway basal cells utilizing engineered zinc-finger nucleases
and single-stranded oligo donor DNA to facilitate gene editing. We specifically focused
on airway basal cells due to their critical role in maintaining the respiratory epithelium.
In a study of DNA double-stranded break-induced gene targeting, it was shown that
80% of gene-targeting events occurred within 45 bp from the DSB (74). Indeed,
research groups have reported efficient ZFN-induced gene editing at or within a few bp
from the DSB (30, 31, 75). In our study, we used ∆F508-specific ZFNs which cut DNA
~8 bp from the ∆F508 mutation which we wish to restore to wild-type sequence
(FIGURE 3.2). We first assessed the efficiency of the ZFNs, delivered in the form of
mRNA via electroporation, to cause DSB in ∆F508/∆F508 airway basal cells. The
advantages of delivering ZFN as mRNA as opposed to plasmid DNA are fourfold: 1)
lower cytotoxicity due to smaller size of RNA, 2) risk of random genome integration is
eliminated, 3) short half-life of RNA lowers the probability of off-target events, and 4)
higher cutting efficiency (26). We found that the addition of WPRE in the 3’ UTR of ZFN
mRNA enhanced % NHEJ ~4 to 12-fold (FIGURE 3.3c), in accordance with previously
reported findings (71). Consistent INDEL rates were obtained between experiments
using commercially-produced ZFN mRNA targeting CFTR ∆F508, and they were found
to be dose-dependent; 25 to 70% NHEJ was achieved, depending on ZFN amount
(FIGURE 3.5).
Donor DNA carrying the correcting sequence is required to facilitate gene correction;
the length of homology arms is a crucial factor in determining its success rate. Using
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ZFNs and a donor plasmid or ssODN, several groups had achieved pre-defined
genomic modifications (26, 30, 31). Using site-specific ZFNs, Chen et al. studied the
efficacies of a 95-mer ssODN to insert a restriction site in the AAVSI locus in 7 different
cell types (26). They showed that the ssODN efficiency was cell-type dependent (a
range of 7 to 57 % insertion rates obtained), and also that the gene modification
obtained using ssODN was ~two-fold higher than that obtained using a plasmid donor. It
was reported by George Church et al. (2014) that having the desired mutation at the
center of the ssODN, preferentially 70-130 bases in length, yielded efficient editing (75).
Therefore, for ∆F508 gene correction, we aimed to optimize gene correction conditions
in CF basal cells using ZFNs and a 100- or 200-mer ssODN; in both cases, the desired
correcting sequence (insertion of CTT) was at the mid-point (FIGURE 3.6A). The 200mer ssODN was found to be more efficient, yielding gene correction rates of ~8-10 %
with 200-400 million copies per cell and thus, was used in our subsequent experiments
(FIGURE 3.6b). We note that a 10% correction frequency per CFTR allele would imply
that between 10 and 20% of cells were corrected depending on whether one or two
alleles were corrected per cell.
We achieved 15.3-17.5% correction with transfection of 4 µg of each ZFN mRNA
and 20 µg of the 200-mer ssODN (2 X 108 copies/cell) (FIGURE 3.7b). Air-liquid
interface system was used for in vitro differentiation of the corrected basal cells into
airway luminal cells and the differentiated cells demonstrated partial restoration of
CFTR channel activity in Ussing chamber assays (ΔIsc values of 3.2 and 4.7 µA/cm2
after forskolin treatment) (FIGURE 3.9).
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We used the CRC technique, in which basal cells are co-cultured with NIH3T3
mouse fibroblasts along with the ROCK inhibitor Y-27362, to enable single-cell clonal
isolation from bulk-corrected basal cells (FIGURE 3.10). Pure corrected clones would
enable us to determine whether correction occurred at one or both alleles. For future
therapeutic use, it is possible that transplantation of a pure clone would be safer since it
could be carefully assayed prior to transplantation for unwanted off-target events. From
our clonal isolation experiment, we obtained one clone having a single wild-type CFTR
allele, out of the 15 clones (30 CFTR alleles) that were analyzed (FIGURE 3.11).
Although at low frequency, this was confirmation of site-specific gene correction. The
clone could not, however, be expanded for further studies due to, we hypothesize,
senescence at high passage number. A vast majority of the clones we obtained were
found to have an INDEL in at least one allele. The consequences of an insertion or
deletion in the immediate vicinity of ΔF508 in exon 11 remains to be determined. This is
an important issue to consider for in vivo editing since the presence of an INDEL in the
place of ΔF508 in both alleles could render it insensitive/unresponsive to the CFTR
triple-drug treatment if eventually utilized as a back-up therapy for the gene editing.
We aimed to further improve our gene correction conditions by editing basal cells at
an earlier passage and by changing the culture medium to increase the proliferation rate
and better retain CFTR activity with passage number. This change of culture medium
required us to re-optimize the editing protocol. In the P-ex plus culture conditions, we
found that the optimum amount of the gene correction reagents that yielded good
correction efficiency with acceptable levels of cytotoxicity was 2 µg each ZFN mRNA
and 20 µg of ssODN (FIGURE 3.13). In three independent repeat experiments using
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these conditions, we obtained correction rates of 7.6-14.2 %. This range of corrected
alleles imply that we obtained 7.6 to 28.4 % cells that where corrected. The edited cells,
which is a mixture of corrected and ΔF508/ΔF508 (with or without INDELs), were ALIdifferentiated and immunofluorescence studies, Western blot & Ussing chamber
analyses were done.
Our reason for performing immunofluorescence studies on the corrected cells was to
check for adverse consequences of gene editing manipulation on the stemness of the
transfected basal cells. Our results, based on quantification of immuno-stained airway
epithelial cell types (basal, secretory, ciliated, and ionocytes), demonstrated that the
differentiation capacities of the manipulated cells were comparable to that of the noncorrected CF and the non-CF cells (FIGURE 3.16). This is an important assessment
since CF therapy employing transplantation of edited cells into the airways will rely on
the stem cell potential of the corrected airway basal cells to repopulate the airway and
differentiate into luminal cells carrying corrected CFTR.
The ΔF508 CFTR protein is pre-maturely degraded in the endoplasmic reticulum and
therefore only core-glycosylated CFTR protein can be detected in Western blot analysis.
Indeed, this was the case in our analysis, where the ΔF508/ΔF508 cells showed
presence of only the immature core-glycosylated CFTR protein (~140 kDa), whereas
non-CF cells demonstrated presence of both mature fully-glycosylated (~170 kDa) and
immature CFTR. The gene-edited samples synthesized mature CFTR protein, albeit not
at the same levels as non-CF controls, as well as its immature form (FIGURE 3.17).
This provided evidence for the ability of our gene correction method to restore fullyglycosylated CFTR protein.
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Comparison of band intensities in the western blots at various exposure times gave a
rough estimation of the total mature CFTR synthesized in the corrected cells (the three
edited replicate samples had 11 – 20.4% of total mature protein as compared to non-CF
cells, respectively). Since trafficking of the CFTR protein to the cellular apical surface of
ciliated cells is necessary for its function, CFTR immunofluorescence studies could
provide information regarding its localization in the corrected cells and the cell types in
which the protein is predominantly present (i. e. ciliated cells versus ionocytes).
By Ussing chamber analysis, we then assessed CFTR ion channel function in the
three edited differentiated samples. An increase in chloride current was observed in the
gene-corrected triplicates when compared with uncorrected CF cells, with the respective
ΔIsc values upon forskolin treatment 6.0 – 9.9 µA/cm2. However, these values were
lower than those obtained in the non-CF control cells, or the CF cells treated with the
VX809 + VX770 drug combination (FIGURE 3.18). These results, although
encouraging, call for further advances (some discussed below) in our current gene
editing strategy to achieve a therapeutically relevant gene editing approach for CF.
After DSB resulting from the action of nucleases such as ZFNs, the cell
predominately utilizes the template-independent NHEJ repair pathway to repair the
lesion. This can be true even in the presence of a donor DNA carrying homologous
sequences. Thus, there has been some effort to shift the balance to HR-mediated repair
by specifically inhibiting the NHEJ pathway. Upon inhibiting DNA ligase IV (which is
required for NHEJ) using SCR7, Hu et al. demonstrated an increase (~two-fold) in Cas9
and ssODN-directed gene modification in human cancer cells (76). Inhibition of a
component of the DSB repair system, 53BP1, which is believed to favor NHEJ over
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HDR, showed an improvement in gene targeting with double-stranded DNA and ZFN by
~5.6-fold (77). Thus, small molecules and inhibitors such as SCR7 and i53 (inhibitor of
53BP1) have the potential to enhance gene correction rates and one of the future goals
of our study could will be to incorporate them to see if they facilitate attaining higher
editing rates.
Another possible avenue for improving ∆F508 editing efficiency would be the delivery
of the ‘correcting’ donor template. Our current strategy of ssODNs is limited both by
toxicity of the delivered nucleic acid as well as the limited size of the homology
sequences. Both limitation could potentially be overcome by donor delivery via viral
vectors such as adeno-associated virus (AAV). AAV is a single-stranded DNA
parvovirus and certain serotypes have been shown to have a natural tropism for lung
epithelium. AAVs can transduce both dividing and non-dividing cells and this is one of
the major advantages of gene transfer using AAV vectors to the slow-proliferating
airway epithelium (77 - 82). Ellis et al. (2013) surveyed ex vivo/in vitro transduction
efficiencies of mammalian primary cells with 10 different AAV serotypes, and they
demonstrated that AAV6 had the greatest ability to transduce a wide range of cell types
(84). Efficient HR-driven genome editing in hematopoietic stem cells has been reported
using ZFN mRNA and AAV6 donors. The relative timings of ZFN and AAV6 delivery are
a crucial determinant of the efficiency of gene editing and it has been shown that AAV6
transduction immediately after ZFN electroporation yields most efficient correction rates
(87). An alternative approach to ssODN-mediated gene correction of CFTR ΔF508
could, therefore, be transducing AAV6 vectors as homologous donor templates after
ZFN electroporation. This method of donor DNA delivery could reduce the cytotoxicity
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we observed in our experiments that resulted from the delivery of ssODNs by
electroporation. AAV6 vectors could potentially carry larger homology arms (they have a
maximum genome packaging size of ~4.5 kb) with less toxic effects on the cells and this
could enhance gene correction to a great extent.
CRISPR/Cas9 is emerging as a new powerful system of genome engineering, in
which the Cas9 DNA nuclease is recruited by a sequence-specific guide RNA (gRNA) to
its target sequence. After the gRNA binds its specific DNA target through sequence
complementation, Cas9 induces DSB (89). Nelson et al. had demonstrated successful
gene correction in a mouse model of Duchenne muscular dystrophy (a genetic disease
resulting from deletions of one or more exons in the dystrophin gene) using the
CRISPR/Cas9 system (90). CRISPR-Cas9 mediated correction of CFTR ΔF508 in
iPSCs has been demonstrated by two groups (91, 92). Therefore, the CRISPR/Cas9
editing system can be an alternative strategy to the ZFN-mediated gene correction
of CFTR ΔF508 mutation.
One major concern in general for nuclease-mediated genome editing is the possibility
of off-target events in the genomic DNA. It will, therefore, be imperative to either
perform whole-genome sequencing on clonal populations or bioinformatically-guided
NGS on predicted off-target sites in order that the corrected cells may be clinically
applicable.
Accomplishing in vivo CF gene editing would require successful delivery of the editing
reagents in the context of mucous-clogged CF airways and also reducing/preventing
host immune responses to gene therapy agents. Clinical translation of the approach
advanced in this project could take two forms. In the first, one could attempt to directly
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edit the airway basal cells in vivo. In the second, ex vivo edited airway basal cells (as
performed in this study, either as a pool of corrected and uncorrected cells or as a
clonal population of corrected cells) could be transplanted back into the lungs of the
affected CF patients. This will require transient injury methods to prepare the lung to
take up the delivered cells. Our achievement in correcting the CFTR ∆F508 mutation
with demonstration of partial restoration of wild-type protein processing and ion channel
activity substantiates that gene modification strategies to treat and/or cure CF is
attainable. With several further improvements, the described correction strategy may
have the potential to bring us closer to ultimately accomplishing a therapeutic gene
editing approach for CF.
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